ADP receptor antagonists as antiplatelet therapeutics

Bibliography

• HELLEM A: The adhesiveness of human blood platelets in vitro. Scand. j Clin. Lab. Invest. (1960) 12:1–17.
   PubMed Web of Science ®Google Scholar
• GAARDNER A, JONSEN A, LALAND S, HELLEM AJ, OWREN P: Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood. Nature (1961) 192:531–532.
   PubMed Web of Science ®Google Scholar
• FELISTE R; DELEBASSEE D, SIMON MF et al.: Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP. Thromb. Res. (1987) 48(4):403–415.
   PubMed Web of Science ®Google Scholar
• MILLS DC: ADP receptors on platelets. Thromb. Haemost. (1996) 76(6):835–856.
   PubMed Web of Science ®Google Scholar
• HULLOPETER G, JANTZEN H-M, VINCENT D et al.: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature (2001) 409(6817):202–207.
   PubMed Web of Science ®Google Scholar
• ••Article describing the isolation and characterisation of the P2Y12 receptor.
   Google Scholar
• FOSTER CJ, PROSSER DM, AGANS JM et al.: Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. I Clin. Invest. (2001) 107(12):1591–1595.
   PubMed Web of Science ®Google Scholar
• TAKASAKI J, KAMOHARA M, SAITO T et al.: Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor. Ma Pharmacol (2001) 60(3):432–439.
   PubMed Web of Science ®Google Scholar
• QUINN MJ, FITZGERALD DJ: Ticlopidine and clopidogrel. Circulation (1999) 100(15):1667–1672.
   PubMed Web of Science ®Google Scholar
• GACHET C: ADP receptors of platelets and their inhibition. Thromb. Haemost. (2001) 86(1):222–232.
   PubMed Web of Science ®Google Scholar
• ••An excellent review on the biology ofplatelet ADP receptors.
   Google Scholar
• RALEVIC V, BURNSTOCK G: Receptors for purines and pyrimidines. Pharmacol Rev (1998) 50(3):413–492.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of nucleoside receptors on all cell types.
   Google Scholar
• JIN J, DANIEL JL, KUNAPULI SP: Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J. Biol. Chem. (1998) 273(4):2030–2034.
   PubMed Web of Science ®Google Scholar
• DANIEL JL, DANGELMAIER C, JIN J, ASHBY B, SMITH JB, KUNAPULI SP: Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J. Biol. Chem. (1998) 273(4):2024–2029.
   PubMed Web of Science ®Google Scholar
• PAUL BZ, DANIEL JL, KUNAPULI SP: Platelet shape change is mediated by both calcium-dependent and -independent signaling pathways. Role of p160 Rho-associated coiled-coil-containing protein kinase in platelet shape change. J. Biol. Chem. (1999) 274(40):28293–28300.
   PubMed Web of Science ®Google Scholar
• JANTZEN HM, GOUSSET L, BHASKAR V et al.: Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation. Thromb. Haemost. (1999) 81(1):111–117.
   PubMed Web of Science ®Google Scholar
• CATTANEO M: Hereditary defect of the platelet ADP receptor(s). Platelets (1998) 9:161–164.
   PubMed Web of Science ®Google Scholar
• NURDEN P, GAUTHIER B, POUJOL C, PASQUET JM, NURDEN AT: Congenital defects of ADP receptors on platelets. Haematologica (2000) 85 (Platelet ADP Receptors Suppl.):46–52.
   Google Scholar
• JANTZEN HM, MILSTONE DS, GOUSSET L, CONLEY PB, MORTENSEN RM: Impared activation of murine platelets lacking Gralphali2.j. Clin. Invest. (2001) 108(3):477–483.
   Google Scholar
• OHLMANN P, ECKLY A, FREUND M, CAZENAVE JP, OFFERMANNS S, GACHET C: ADP induces partial platelet aggregation without shape change and potentiates collagen-induced aggregation in the absence of Galphaq. Blood (2000) 96(6):2134–2139.
   PubMed Web of Science ®Google Scholar
• KAUFFENSTEIN G, BERGMEIER W, ECKLY A et al.: The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin-a phosphoinositide 3-kinase-dependent mechanism. FEBS Lett (2001) 505(2):281–290.
   PubMed Web of Science ®Google Scholar
• VALERA S, HUSSY N, EVANS RJ et al: A new class of ligand-gated ion channel defined by P2x receptor for extracellular ATP. Nature (1994) 371(6497):516–519.
   PubMed Web of Science ®Google Scholar
• BRAKE AJ, WAGENBACH MJ, JULIUS D: New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor. Nature (1994) 371(6497):519–523.
   PubMed Web of Science ®Google Scholar
• SAVI P, COMBALBERT J, GAICH C et al.: The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb. Haemost. (1994) 72(2):313–317.
   PubMed Web of Science ®Google Scholar
• LAU WC, WASKELL LA, WATKINS PB et al.: Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation (2003) 107(1):32–37.
   PubMed Web of Science ®Google Scholar
• SAVI P, PEREILLO JM, UZIBIAGA MF et al.: Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haemost. (2000) 84(5):891–896.
   PubMed Web of Science ®Google Scholar
• GENT M, BLAKELY JA, EASTON JD et al.: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet (1989) 1 (8649):1215–1220.
   PubMed Web of Science ®Google Scholar
• CAPRIE STEERING COMMITTEE: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet (1996) 348(9039):1329–1339.
   PubMedGoogle Scholar
• YUSUF S, ZHAO F, MEHTA SR, CHROLAVICIUS S, TOGNONI G, FOX KK: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl. J. Med. (2001) 345(7):494–502.
   PubMed Web of Science ®Google Scholar
• SCHOMIG A, NEUMANN FJ, KASTRATI A et al: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl. J. Med. (1996) 334(17):1084–1089.
   PubMed Web of Science ®Google Scholar
• BERTRAND ME, LEGRAND V, BOLAND J et al.: Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation (1998) 98(16):1597–1603.
   PubMed Web of Science ®Google Scholar
• URBAN P, MACAYA C, RUPPRECHT HJ et al.: Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation (1998) 98(20):2126–2132.
   PubMed Web of Science ®Google Scholar
• MEHTA SR, YUSUF S, PETERS RJ et al: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 358(9281):527–533.
   PubMed Web of Science ®Google Scholar
• STEINHUBL SR, BERGER PB, MANN JT et al.: Clopidogrel for the reduction of events during observation. CREDO investigators. Am. Med. Assoc. (2002) 288(19):2411–2420.
   PubMed Web of Science ®Google Scholar
• BONEU B, DESTELLE G: Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients. Thromb. Haemost. (1996) 76(6):939–943.
   PubMed Web of Science ®Google Scholar
• BENNETT CL, CONNORS, JM, CARWILE JM et al: Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl. Med. (2000) 342(24):1773–1777.
   PubMed Web of Science ®Google Scholar
• TANIUCHI M, KURZ HI, LASALA JM: Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population. Circulation (2001) 104(5):539–543.
   PubMed Web of Science ®Google Scholar
• SUGIDACHI A, ASAI F, OGAWA T, INOUE T, KOIKE H: The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br. Pharmacol (2000) 129(7):1439–1446.
   PubMed Web of Science ®Google Scholar
• SUGIDACHI A, ASAI F, YONEDA K et al.: Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747.Br. J. Pharmacol (2001) 132(1)47–54.
   PubMedGoogle Scholar
• CUSACK NJ, HOURANI SM: Adenosine 5-diphosphate antagonists and human platelets: no evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated by different receptors. Br. J. Pharmacol (1982) 76(1):221–227.
   PubMed Web of Science ®Google Scholar
• HUMPHRIES RG, ROBERTSON MJ, LEFF P: A novel series of P2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends Pharmacol Sci (1995) 16(6):179–181.
   PubMed Web of Science ®Google Scholar
• HUMPHRIES RG, TOMLINSON W, INGALL AH, CAGE PA, LEFF P: FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors. Br. Pharmacol (1994) 113(3):1057–1063.
   PubMed Web of Science ®Google Scholar
• HUMPHRIES RG, TOMLINSON W, CLEGG JA, INGALL AH, KINDON ND, LEFF P: Pharmacological profile of the novel P2T-purinoceptor antagonist, FPL 67085 in vitro and in the anaesthetized rat in vivo. Br. Pharmacol. (1995) 115(6):1110–1116.
   Google Scholar
• INGALL AH, DIXON J, BAILEY A et al.: Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. Med. Chem. (1999) 42(2):213–220.
   Web of Science ®Google Scholar
• HUANG J, DRISCOLL EM, GONZALES ML, PARK AM, LUCCHESI BR: Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model. Pharmacol Exp. Ther. (2000) 295(2):492–499.
   PubMed Web of Science ®Google Scholar
• CHATTARAJ SC: Cangrelor AstraZeneca. CLIFF. Opin. Invest. Drugs. (2001) 2(2):250–255.
   PubMedGoogle Scholar
• STOREY RE OLDROYD KG, WILCOX RG: Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb. Haemost. (2001) 85(3):401–407.
   PubMed Web of Science ®Google Scholar
• SCARBOROUGH RM, LAIBELMAN AM, CLIZBE LA et al: Novel tricyclic benzothiazolo [2,3-C]thiadiazine antagonists of the platelet ADP receptor (P2Y(12)). Bioorg. Med. Chem. Lett (2001) 11(14):1805–1808.
   PubMed Web of Science ®Google Scholar